Meta-analysis: the effect of interferon on development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection

[1]  S. Fan,et al.  Sustained disease remission after spontaneous HBeAg seroconversion is associated with reduction in fibrosis progression in chronic hepatitis B Chinese patients , 2007, Hepatology.

[2]  Chien-Jen Chen,et al.  Risk and predictors of mortality associated with chronic hepatitis B infection. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[3]  M. Buti,et al.  Peginterferon alpha‐2b is safe and effective in HBeAg‐positive chronic hepatitis B patients with advanced fibrosis , 2007, Hepatology.

[4]  Roger Williams,et al.  Genetic characteristics of hepatitis B virus genotypes as a factor for interferon‐induced HBeAg clearance , 2007, Journal of medical virology.

[5]  Xinyue Chen,et al.  Intrahepatic HBV DNA as a predictor of antivirus treatment efficacy in HBeAg-positive chronic hepatitis B patients. , 2007, World journal of gastroenterology.

[6]  M. Mizokami,et al.  Genotype B and younger patient age associated with better response to low-dose therapy: a trial with pegylated/nonpegylated interferon-alpha-2b for hepatitis B e antigen-positive patients with chronic hepatitis B in China. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  P. Marcellin,et al.  Predicting response to peginterferon α-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B , 2006, Gut.

[8]  H. Janssen,et al.  Successful Treatment with Peginterferon alfa-2b of HBeAg-positive HBV Non-Responders to Standard Interferon or Lamivudine , 2006, The American Journal of Gastroenterology.

[9]  B. Bell,et al.  The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. , 2006, Journal of hepatology.

[10]  H. Janssen,et al.  Treatment with Peg-Interferon α-2b for HBeAg-Positive Chronic Hepatitis B: HBsAg Loss Is Associated with HBV Genotype , 2006, The American Journal of Gastroenterology.

[11]  M. Washington,et al.  A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B. , 2006, Archives of internal medicine.

[12]  Guan-Tarn Huang,et al.  Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. , 2006, JAMA.

[13]  Thomas Berg,et al.  Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. , 2005, The New England journal of medicine.

[14]  G. Yamada,et al.  Influence of viral load and genotype in the progression of Hepatitis B‐associated liver cirrhosis to hepatocellular carcinoma , 2005, Liver international : official journal of the International Association for the Study of the Liver.

[15]  Yoshiyuki Suzuki,et al.  Hepatitis B Virus-Related Hepatocellular Carcinogenesis and Its Prevention , 2005, Intervirology.

[16]  S. Schaefer.  Hepatitis B virus: significance of genotypes , 2005, Journal of viral hepatitis.

[17]  Chien-Jen Chen,et al.  Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. , 2005, Journal of the National Cancer Institute.

[18]  Y. Ohashi,et al.  Antiviral Therapy for Cirrhotic Hepatitis C: Association with Reduced Hepatocellular Carcinoma Development and Improved Survival , 2005, Annals of Internal Medicine.

[19]  Oliver N Keene,et al.  Lamivudine for patients with chronic hepatitis B and advanced liver disease. , 2004, The New England journal of medicine.

[20]  P. Marcellin,et al.  Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. , 2004, The New England journal of medicine.

[21]  V. Wong,et al.  Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma , 2004, Gut.

[22]  C. Chu,et al.  Comparison of long‐term effects of lymphoblastoid interferon alpha and recombinant interferon alpha‐2a therapy in patients with chronic hepatitis B , 2004, Journal of viral hepatitis.

[23]  D. Lavanchy,et al.  Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures , 2004, Journal of viral hepatitis.

[24]  M. Wulfsohn,et al.  Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. , 2003, The New England journal of medicine.

[25]  A. Lok,et al.  HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C. , 2002, Hepatology.

[26]  Chien-Jen Chen,et al.  Hepatitis B e antigen and the risk of hepatocellular carcinoma. , 2002, The New England journal of medicine.

[27]  H. Chiou,et al.  Long‐term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B , 2002, Hepatology.

[28]  P. Tangkijvanich,et al.  Long-term effect of interferon therapy on incidence of cirrhosis and hepatocellular carcinoma in Thai patients with chronic hepatitis B. , 2001, The Southeast Asian journal of tropical medicine and public health.

[29]  P. Andreone,et al.  Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. , 2001, Journal of hepatology.

[30]  S. Hadziyannis,et al.  The long-term outcome of interferon-α treated and untreated patients with HBeAg-negative chronic hepatitis B , 2001 .

[31]  T. Kosugi,et al.  Long-term outcome of chronic hepatitis B in adolescents or young adults in follow-up from childhood. , 2000, Journal of pediatric gastroenterology and nutrition.

[32]  E. Schiff,et al.  Lamivudine as initial treatment for chronic hepatitis B in the United States. , 1999, The New England journal of medicine.

[33]  C. Chu,et al.  Long‐term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection , 1999, Hepatology.

[34]  N. Leung,et al.  A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. , 1998, The New England journal of medicine.

[35]  K. Chayama,et al.  Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus , 1998, Cancer.

[36]  C. Begg,et al.  Operating characteristics of a rank correlation test for publication bias. , 1994, Biometrics.

[37]  A. Detsky,et al.  Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B , 1993, Annals of Internal Medicine.

[38]  R. D. de Man,et al.  Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. , 1992, Gastroenterology.

[39]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[40]  C. Chu,et al.  Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. , 2007, Journal of hepatology.

[41]  P. Loehrer,et al.  Risk of Hepatocellular Carcinoma Across a Biological Gradient of Serum Hepatitis B Virus DNA Level , 2007 .

[42]  M. Campbell.  Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis BLau GKK, for the Peginterferon Alfa-2a HBeAg-Positive Chronic Hepatitis B Study Group (Univ of Hong Kong, China; et al) N Engl J Med 352:2682–2695, 2005§ , 2006 .

[43]  S. Locarnini.  Molecular virology and the development of resistant mutants: implications for therapy. , 2005, Seminars in liver disease.

[44]  A. Craxì,et al.  Interferon-α for HBeAg-positive chronic hepatitis B , 2003 .

[45]  A. Pezzoli,et al.  Long-term results with interferon therapy in chronic type B hepatitis: a prospective randomized trial , 1999, American Journal of Gastroenterology.

[46]  L. Benvegnu'.  Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. International Interferon-alpha Hepatocellular Carcinoma Study Group. , 1998, Lancet.

[47]  A. Liberati,et al.  Interferon treatment in patients with chronic hepatitis B: a meta-analysis of the published literature. , 1993, Journal of hepatology.